Montana is currently home to 262 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Billings, Missoula, Great Falls and Kalispell. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Prospective Research Assessment in Multiple Myeloma: An Observational Evaluation (PREAMBLE)
NCT01838512
Recruiting
The purpose of this study is to assess the clinical effectiveness of all approved multiple myeloma (MM) therapies in the newly-diagnosed (NDMM) and the relapsed/refractory MM (RRMM) settings in real-world clinical practice.
Gender:
All
Ages:
18 years and above
Trial Updated:
02/16/2023
Locations: Local Institute, Missoula, Montana
Conditions: Multiple Myeloma
Register for Updates
Buccal Film vs IV Palonosetron for Prevention of CINV in Cancer Patients Receiving MEC
NCT05199818
Recruiting
The phase 3 study is to compare the efficacy and safety of palonosetron, a long-acting 5-HT3 receptor antagonist, by buccal film delivery compared to IV injection for the prevention of chemotherapy-induced nausea and vomiting. Subjects receive a single dose of palonosetron prior to moderately emetogenic chemotherapy.
Gender:
All
Ages:
18 years and above
Trial Updated:
01/19/2023
Locations: St. Vincent Frontier Cancer Center, Billings, Montana
Conditions: Chemotherapy-induced Nausea and Vomiting
Register for Updates
Testing the Use of Targeted Treatment (AMG 510) for KRAS G12C Mutated Advanced Non-squamous Non-small Cell Lung Cancer (A Lung-MAP Treatment Trial)
NCT04625647
Recruiting
This phase II Lung-MAP treatment trial studies the effect of AMG 510 in treating non-squamous non-small cell lung cancer that is stage IV or has come back (recurrent) and has a specific mutation in the KRAS gene, known as KRAS G12C. Mutations in this gene may cause the cancer to grow. AMG 510, a targeted treatment against the KRAS G12C mutation, may help stop the growth of tumor cells.
Gender:
All
Ages:
18 years and above
Trial Updated:
11/09/2022
Locations: Community Hospital of Anaconda, Anaconda, Montana
Conditions: Lung Adenocarcinoma, Lung Non-Small Cell Carcinoma, Recurrent Lung Non-Squamous Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8, Stage IVB Lung Cancer AJCC v8
Register for Updates
Connect® Myeloid Disease Registry
NCT01688011
Recruiting
The purpose of the Connect® Myeloid disease registry is to provide unique insights into treatment decisions and treatment patterns as they relate to clinical outcomes of patients with myeloid diseases in routine clinical practice. This disease registry will also evaluate molecular and cellular markers that may provide further prognostic classification which may or may not be predictive of therapy and clinical outcomes.
Gender:
All
Ages:
18 years and above
Trial Updated:
10/25/2022
Locations: Billings Clinic, Billings, Montana
Conditions: Myelodysplastic Syndromes, Primary Myelofibrosis, Leukemia, Myeloid, Acute
Register for Updates
Home With TablO outcoMEs (HOME) Registry
NCT04526301
Recruiting
Prospective, multicenter, single arm, post-market study to evaluate real world clinical outcomes in ESRD patients receiving in-home dialysis on the Tablo Hemodialysis System.
Gender:
All
Ages:
15 years and above
Trial Updated:
09/22/2022
Locations: St. Peter's Health, Helena, Montana
Conditions: End Stage Renal Disease
Register for Updates
An Exploratory, Open-Label, Oligo-Center Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Intravenous DNV3837 in Subjects With Clostridium Difficile Infection
NCT03988855
Recruiting
This is an open-label study to evaluate the safety, efficacy, and PK of DNV3837 at a dose of 1.5 mg/kg actual body weight(BW)/day administered via IV infusion in subjects with CDI. The study will be conducted in 2 subsequent parts. In Part 1 of the study, 10 subjects of either sex with severe or non-severe CDI will be enrolled to receive DNV3837. In Part 2 of the study, up to 30 subjects with severe or non-severe CDI will be enrolled to receive DNV3837. In both parts of the study, treatment i... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
09/06/2022
Locations: Mercury Street Medical, Butte, Montana
Conditions: Clostridium Difficile (C. Difficile)
Register for Updates
Adipose-Derived Biocellular Regenerative Therapy for Osteoarthritis
NCT04238143
Recruiting
Use of Biocellular and cellular approaches to treatment of Osteoarthritis (OA), musculoskeletal aging processes, pain, and degenerative changes are to be studied with minimally invasive protocols, and non-pharmaceutical means to relieve OA and its associated issues. Traditional surgical interventions have not yielded convincing long-term outcomes, including total joint replacement surgeries and medical management of the supportive structures. This study is to use a person's own stem/stromal Cel... Read More
Gender:
All
Ages:
Between 18 years and 90 years
Trial Updated:
04/07/2022
Locations: Regenevita LLC, Stevensville, Montana
Conditions: Osteoarthritis, Osteo Arthritis Knee, Osteo Arthritis Shoulders, Osteoarthritis of Multiple Joints, Osteoarthritis, Hip, Osteoarthritis - Ankle/Foot
Register for Updates
Prospective US Radiofrequency SUI Trial
NCT04720352
Recruiting
PURSUIT: Prospective US Radiofrequency SUI Trial (VI-17-06) is a prospective, randomized, sham controlled, double blind study in premenopausal women with stress urinary incontinence. The study will be conducted in 390 subjects, randomized 2:1 with active or sham treatment. Study duration is 12 months post treatment. The primary objective is to evaluate the efficacy of the Viveve treatment, SUI protocol, in improving mild to moderate stress urinary incontinence (SUI), assessed using the 1-hour Pa... Read More
Gender:
Female
Ages:
18 years and above
Trial Updated:
07/19/2021
Locations: Boeson Research, Missoula, Montana
Conditions: Urinary Incontinence, Stress
Register for Updates
The PRIME Study: A Randomized, Controlled, Prospective Study
NCT04549935
Recruiting
To investigate the outcomes of patients undergoing bilateral RLE surgery with treatment of dexamethasone intracanilicular insert compared to topical standard care steroid. Desiged to look at patient preference comparing the insert to drops and will also look at patient outcomes including inflammatin and risk of cystoid macular edema post-operatively.
Gender:
All
Ages:
Between 22 years and 75 years
Trial Updated:
09/14/2020
Locations: Briana Parker, Bozeman, Montana
Conditions: Patient Preference, Patient Outcomes, Post-Operative Inflammation, Grade of Post-Operative Cystoid Macular Edema, Rate of Post-Operative Cystoid Macular Edema
Register for Updates
Biocellular-Cellular Regenerative Treatment Scaring Alopecia and Alopecia Areata
NCT03078686
Recruiting
The primary objective of this study is to evaluate the safety and efficacy of the use of a biocellular mixture of emulsified adipose-derived tissue stromal vascular fraction (AD-tSVF) and high density platelet-rich plasma concentrate (HD- PRP). Additionally, comparison with clinical outcomes of adipose-derived cellular Stromal Vascular Fraction (AD-cSVF) + AD-tSVF + HD PRP; AD-cSVF + emulsified AD-tSVF + HD- PRP; emulsified AD-tSVF + HD PRP + AD-cSVF; AD-cSVF via intravenous infusion in treatmen... Read More
Gender:
All
Ages:
Between 18 years and 75 years
Trial Updated:
04/15/2020
Locations: Regenevita LLC, Stevensville, Montana
Conditions: Alopecia Areata, Scarring Alopecia
Register for Updates